UY26616A1 - Anticuerpos específicos de fap- alfa humanos - Google Patents

Anticuerpos específicos de fap- alfa humanos

Info

Publication number
UY26616A1
UY26616A1 UY26616A UY26616A UY26616A1 UY 26616 A1 UY26616 A1 UY 26616A1 UY 26616 A UY26616 A UY 26616A UY 26616 A UY26616 A UY 26616A UY 26616 A1 UY26616 A1 UY 26616A1
Authority
UY
Uruguay
Prior art keywords
alpha
fap
humans
specific antibodies
antibodies
Prior art date
Application number
UY26616A
Other languages
English (en)
Inventor
John Park
Dr Pilar Garin-Chesa
Dr Klaus Pfizenmaier
Dr Dieter Moosmayer
Michael Mersmann
Alexej Schmidt
Original Assignee
Boheringer Ingelheim Pharma Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boheringer Ingelheim Pharma Kg filed Critical Boheringer Ingelheim Pharma Kg
Publication of UY26616A1 publication Critical patent/UY26616A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se refiere a proteínas de anticuerpos que se unen específicamente a proteínas activadora de fibroblastos alfa (FAP-alfa. La invención se refiere, además, al uso de dichos anticuerpos para fines de diagnóstico y terapéuticos, así como a procedimientos para preparar dichos anticuerpos.
UY26616A 2000-03-17 2001-03-14 Anticuerpos específicos de fap- alfa humanos UY26616A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10013286A DE10013286A1 (de) 2000-03-17 2000-03-17 Humane FAP-alpha-spezifische Antikörper

Publications (1)

Publication Number Publication Date
UY26616A1 true UY26616A1 (es) 2001-10-25

Family

ID=7635287

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26616A UY26616A1 (es) 2000-03-17 2001-03-14 Anticuerpos específicos de fap- alfa humanos

Country Status (3)

Country Link
AR (1) AR028262A1 (es)
DE (1) DE10013286A1 (es)
UY (1) UY26616A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014167083A1 (en) 2013-04-12 2014-10-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the risk of developing a colonic neoplasia
WO2023125796A1 (en) * 2021-12-30 2023-07-06 Concept To Medicine Biotech Co., Ltd. Human antibodies against fap-alpha

Also Published As

Publication number Publication date
DE10013286A1 (de) 2001-09-20
AR028262A1 (es) 2003-04-30

Similar Documents

Publication Publication Date Title
CR8231A (es) Anticuerpos rg1 y uso de los mismos
CY1119291T1 (el) Πολυσθενη αντισωματα και χρησεις για αυτα
CY1118880T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
EA201100694A1 (ru) Антитело к cd38 человека и его применение
ATE411082T1 (de) Neue verwendung von kurzkettigen carbonsäuren
CR10878A (es) Anticuerpos para cd40 (divisional de exp. 7343)
ECSP10010653A (es) Anticuerpos anti-il-17a/il-17f de reactividad cruzada y métodos de uso de los mismos
CO6531481A2 (es) Proteinas de enlace al antigeno il-23 humanas
UA109633C2 (uk) Антитіло людини проти тканинного фактора
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
NO20041917D0 (no) Spesifikke midler som binder humant angiopoietin-2
FI1897548T4 (fi) T-solujen säätely
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
AU9399501A (en) Therapeutic antibodies
ATE476992T1 (de) Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper
DE60226486D1 (de) Selbstanordnende moleküle
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
CL2008001258A1 (es) Kit de vacuna que comprende al menos nueve conjugados de sacaridos de antgenos hb o hib, donde al menos 2-7 son con la proteina transportadora crm, siendo dicho kit adecuado para usar en su calendario de inmunizacion primaria; vacuna combinada adecuada para la inmunizacion primaria.
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
DE50111331D1 (de) Neue verwendung von proteinhydrolysaten
CO2023001559A2 (es) Anticuerpos fgfr3 y métodos de uso
BR0116686A (pt) Anticorpos anti-cd28 silenciados e uso dos mesmos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140908